Piper Sandler Downgrades CymaBay Therapeutics to Neutral, Lowers Price Target to $32.5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi downgraded CymaBay Therapeutics (CBAY) from Overweight to Neutral and reduced the price target from $33 to $32.5.

February 14, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CymaBay Therapeutics was downgraded by Piper Sandler from Overweight to Neutral, with a price target adjustment from $33 to $32.5.
The downgrade from Overweight to Neutral by a significant analyst like Piper Sandler suggests a less optimistic outlook on CBAY's stock performance in the short term. The slight reduction in the price target further indicates a tempered expectation for the stock's growth potential. These factors are likely to influence investor sentiment negatively, potentially leading to a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100